JNJ最近会上讨论Carvykti前景：
JNJ Highlighted Carvykti's Unprecedented Long-term Remission in Late-line RRMM and Initial
ORR of Its BCMAxGPRC5DxCD3 Trispecific Antibody Presented at ASCO 2025. Carvykti reported
5-year PFS in 33% patients (32/97) from the CARTITUDE-1 trial in 5L+ MM, with mOS of 60.6m. The
CARTITUDE-1 study had enrolled heavily pretreated patients with a median of 6 prior LOT. Thus,
achieving 33% 5-year PFS rate is highly remarkable, unprecedented for this patient population given
disease heterogeneity, per docs. JNJ-5322 is a trispecific antibody targeting BCMA and GPRC5D via
T-cell redirection. It reported 73-100% ORR in BCMA/GPRC5D-naive pretreated MM patients. Noting
these clinical data, JNJ expressed bullishness in its multiple myeloma franchise, and anticipates
the growth to be a stronghold.
$金斯瑞生物科技(01548)$ $传奇生物(LEGN)$ $强生(JNJ)$